Emicizumab prophylaxis and health-related outcomes in persons with hemophilia a (PwHA) with inhibitors: HAVEN 1 study

被引：0

作者：

Oldenburg, J. ^{[1
]}

Mahlangu, J. N. ^{[2
,3
]}

Bujan, W. ^{[4
]}

Trask, P. C. ^{[5
]}

von Mackensen, S. ^{[6
]}

Callaghan, M. U. ^{[7
]}

Young, G. ^{[8
]}

Asikanius, E. ^{[9
]}

Peyvandi, F. ^{[10
]}

Santagostino, E. ^{[10
]}

Kruse-Jarres, R. ^{[11
]}

Negrier, C. ^{[12
]}

Kessler, C. ^{[13
]}

Levy, G. G. ^{[14
]}

Windyga, J. ^{[15
]}

Shima, M. ^{[16
]}

机构：

[1] Univ Klinikum Bonn, Bonn, Germany

[2] Univ Witwatersrand, Fac Hlth Sci, Haemophilia Comprehens Care Ctr, Johannesburg, South Africa

[3] NHLS, Johannesburg, South Africa

[4] Inst Costarricense Invest Cient, San Jose, Costa Rica

[5] Genentech Inc, San Francisco, CA 94080 USA

[6] Univ Med Ctr Hambur Eppendorf, Dept Med Psychol, Hamburg, Germany

[7] Childrens Hosp Michigan, Detroit Med Ctr, Detroit, MI 48201 USA

[8] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA

[9] F Hoffmann La Roche Ltd, Basel, Switzerland

[10] Osped Maggiore Policlin, IRCCS Ca Granda Fdn, Milan, Italy

[11] Univ Washington, Washington Ctr Bleeding Disorders BloodWorks NW, Seattle, WA 98195 USA

[12] Univ Claude Bernard, Louis Pradel Cardiol Hosp, Lyon, France

[13] Georgetown Univ, Med Ctr, Washington, DC 20007 USA

[14] Genentech Inc, Pharma Dev Oncol, San Francisco, CA 94080 USA

[15] Inst Hematol & Transfus Med, Warsaw, Poland

[16] Nara Med Univ, Dept Pediat, Kashihara, Nara, Japan

来源：

HAEMOPHILIA | 2018年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P120

引用

页码：89 / 90

页数：2

共 50 条

[31] Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies [J].

Mahlangu, Johnny ;

Jimenez-Yuste, Victor ;

Ventriglia, Giuliana ;

Niggli, Markus ;

Barlera, Simona ;

Hermans, Cedric ;

Lehle, Michaela ;

Chowdary, Pratima ;

Jew, Lyle ;

Windyga, Jerzy ;

Frenzel, Laurent ;

Schmitt, Christophe ;

Castaman, Giancarlo ;

Pipe, Steven W. .

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (02)

[32] Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study [J].

Mancuso, Maria Elisa ;

Mahlangu, Johnny ;

Sidonio, Robert, Jr. ;

Trask, Peter ;

Uguen, Marianne ;

Chang, Tiffany ;

Shima, Midori ;

Young, Guy ;

Oldenburg, Johannes ;

von Mackensen, Sylvia .

HAEMOPHILIA, 2020, 26 (06) :1009-1018

[33] Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII [J].

Fredrik Jonsson ;

Christophe Schmitt ;

Claire Petry ;

Francois Mercier ;

Nicolas Frey ;

Sylvie Retout .

Clinical Pharmacokinetics, 2021, 60 :931-941

[34] Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study [J].

Kiialainen, Anna ;

Niggli, Markus ;

Kempton, Christine L. ;

Castaman, Giancarlo ;

Chang, Tiffany ;

Paz-Priel, Ido ;

Adamkewicz, Joanne, I ;

Levy, Gallia G. .

HAEMOPHILIA, 2022, 28 (06) :1033-1043

[35] Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities - Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY) [J].

Jimenez-Yuste, Victor ;

Oldenburg, Johannes ;

Tzeng, Eunice ;

Trzaskoma, Ben ;

Sanabria, Fabian ;

Mahlangu, Johnny .

BLOOD, 2021, 138

[36] Factor VIII use in the treatment of breakthrough bleeds in persons with haemophilia a without inhibitors on emicizumab prophylaxis: the phase III HAVEN 3 study experience [J].

Callaghan, M. ;

Trzaskoma, B. ;

Ko, R. ;

Lee, L. ;

Patel, A. ;

Tzeng, E. ;

Shah, M. ;

Chang, T. ;

Niggli, M. ;

Dhalluin, C. ;

Paz-Priel, I. ;

Mahlangu, J. .

BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 :44-45

[37] Health-related quality of life of patients with hemophilia and inhibitors [J].

Lee, W. C. ;

Brown, M. ;

Joshi, A., V ;

Foster, T. ;

Pashos, C. L. .

VALUE IN HEALTH, 2008, 11 (03) :A164-A164

[38] Health-related quality of life in patients with hemophilia and inhibitors [J].

Lee, W. ;

Brown, M. ;

Joshi, A. ;

Pashos, C. .

HAEMOPHILIA, 2008, 14 :47-47

[39] Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4) [J].

Callaghan, Michael U. ;

Negrier, Claude ;

Paz-Priel, Ido ;

Chang, Tiffany ;

Chebon, Sammy ;

Lehle, Michaela ;

Mahlangu, Johnny ;

Young, Guy ;

Kruse-Jarres, Rebecca ;

Mancuso, Maria Elisa ;

Niggli, Markus ;

Kuebler, Peter ;

Bienz, Nives Selak ;

Shima, Midori ;

Jimenez-Yuste, Victor ;

Schmitt, Christophe ;

Asikanius, Elina ;

Levy, Gallia ;

Pipe, Steven W. ;

Oldenburg, Johannes .

BLOOD, 2020, 136

[40] Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors [J].

Castaman, Giancarlo ;

Peyvandi, Flora ;

Hovinga, Johanna A. Kremer ;

Schutgens, Roger E. G. ;

Robson, Susan ;

Moreno, Katya ;

Jimenez-Yuste, Victor .

TH OPEN, 2024, 08 (01) :e42-e54

← 1 2 3 4 5 →